These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36289231)

  • 1. Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome.
    Fulton SL; Wenderski W; Lepack AE; Eagle AL; Fanutza T; Bastle RM; Ramakrishnan A; Hays EC; Neal A; Bendl J; Farrelly LA; Al-Kachak A; Lyu Y; Cetin B; Chan JC; Tran TN; Neve RL; Roper RJ; Brennand KJ; Roussos P; Schimenti JC; Friedman AK; Shen L; Blitzer RD; Robison AJ; Crabtree GR; Maze I
    Nat Commun; 2022 Oct; 13(1):6384. PubMed ID: 36289231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
    Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear Reorganization in Hippocampal Granule Cell Neurons from a Mouse Model of Down Syndrome: Changes in Chromatin Configuration, Nucleoli and Cajal Bodies.
    Puente-Bedia A; Berciano MT; Tapia O; Martínez-Cué C; Lafarga M; Rueda N
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits.
    Zhang L; Meng K; Jiang X; Liu C; Pao A; Belichenko PV; Kleschevnikov AM; Josselyn S; Liang P; Ye P; Mobley WC; Yu YE
    Hum Mol Genet; 2014 Feb; 23(3):578-89. PubMed ID: 24041763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways to cognitive deficits in Down syndrome.
    Sturgeon X; Le T; Ahmed MM; Gardiner KJ
    Prog Brain Res; 2012; 197():73-100. PubMed ID: 22541289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome.
    Velazquez R; Ash JA; Powers BE; Kelley CM; Strawderman M; Luscher ZI; Ginsberg SD; Mufson EJ; Strupp BJ
    Neurobiol Dis; 2013 Oct; 58():92-101. PubMed ID: 23643842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits.
    Busciglio J; Capone G; O'Bryan J; Gardiner KJ
    Cytogenet Genome Res; 2013; 141(4):260-71. PubMed ID: 24008277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.
    Ahmed MM; Dhanasekaran AR; Block A; Tong S; Costa AC; Stasko M; Gardiner KJ
    PLoS One; 2015; 10(3):e0119491. PubMed ID: 25793384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
    Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.
    Gardiner KJ
    Drug Des Devel Ther; 2015; 9():103-25. PubMed ID: 25552901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
    Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ
    Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of trisomic proteins in Down syndrome model systems.
    Spellman C; Ahmed MM; Dubach D; Gardiner KJ
    Gene; 2013 Jan; 512(2):219-25. PubMed ID: 23103828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD).
    Alldred MJ; Lee SH; Petkova E; Ginsberg SD
    Brain Struct Funct; 2015 Sep; 220(5):2983-96. PubMed ID: 25031177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome.
    Aziz NM; Guedj F; Pennings JLA; Olmos-Serrano JL; Siegel A; Haydar TF; Bianchi DW
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29716957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome.
    Brault V; Nguyen TL; Flores-Gutiérrez J; Iacono G; Birling MC; Lalanne V; Meziane H; Manousopoulou A; Pavlovic G; Lindner L; Selloum M; Sorg T; Yu E; Garbis SD; Hérault Y
    PLoS Genet; 2021 Sep; 17(9):e1009777. PubMed ID: 34587162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.
    Rueda N; Flórez J; Martínez-Cué C
    Neural Plast; 2012; 2012():584071. PubMed ID: 22685678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Mmu17 Non-Hsa21 Orthologous Genes in the Ts65Dn Mouse Model of Down Syndrome: The Gold Standard Refuted.
    Guedj F; Kane E; Bishop LA; Pennings JLA; Herault Y; Bianchi DW
    Biol Psychiatry; 2023 Jul; 94(1):84-97. PubMed ID: 37074246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.
    Ruparelia A; Pearn ML; Mobley WC
    Curr Opin Neurobiol; 2012 Oct; 22(5):880-6. PubMed ID: 22658745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.